Stock Ratings / Health Care / ALVO / options

COAG (57) VIR (31) MESO (60) MAZE (45) ⌘ Pro Terminal →

Alvotech (ALVO) Options Positioning, Max Pain & Unusual Sweeps

$4.89 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.87

Alvotech (ALVO) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.91B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.87 (-0.37%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALVO)Realized 20D OHLCV Swing Band: ±11.1%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY ALVO SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 38.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$5.78-13.5% Next Q

Q2 (-2Q)

Grade C+$5.00-8.4% Next Q

Q3 (-1Q)

Grade C$4.58+6.8% Next Q

Current

Grade D+$4.89+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALVO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, ALVO faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.32) or 200D SMA ($4.21) invalidates the momentum regime and cuts Target Base ($4.89) toward Bear Floor ($3.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±11.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ALVO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ALVO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALVO)

✓Walkthrough of ALVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.41%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.85H $4.89L $4.55C $4.89VOL 714.8K

RES: $6.99SUP: $4.61SMA50: $5.32SMA200: $4.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALVO Butterfly Map → + Track ALVO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALVO)

Health Care Rank #226 of 1016 ⚔️ COAG vs ALVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALVO vs. COAG, VIR, MESO, MAZE)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alvotech (ALVO) ranks #226 by composite RQD confidence (58/100, grade D+) and #270 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, ALVO leads on earnings valuation at N/A trailing P/E, while VIR leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. MESO currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with ALVO at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALVO ACTIVE Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	Benchmark Subject
COAG Hemab Therapeutics Holdings Inc.	D+	57/100	—	—	—	+4.99%	$1.89B	/coag-vs-alvo →
VIR Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	/vir-vs-alvo →
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-alvo →
MAZE Maze Therapeutics Inc.	D	45/100	—	—	-35.0%	+0.63%	$1.77B	/maze-vs-alvo →

2. ALVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Alvotech (ALVO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.91B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ALVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Alvotech (NASDAQ: ALVO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $4.89 (-1.01% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ALVO ranks #226 in composite RQD confidence.

How does ALVO compare to COAG and VIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALVO carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COAG (Hemab Therapeutics Holdings Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $1.89B) and VIR (Vir Biotechnology Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.01B). Among the 5-stock peer group, ALVO leads on earnings multiple (N/A) while VIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALVO?

For Alvotech (ALVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #226 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALVO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALVO last traded at $4.89 (-1.01% on volume of 373,425 shares), positioning the stock -8.08% below its 50-day simple moving average ($5.32) and +16.15% above its 200-day simple moving average ($4.21). Across its 52-week range of $2.94 to $6.53, ALVO sits at the 54.3% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($4.35 to $5.43).